IP Library Granted Patent US 8,900,594
Granted Patent B2
US 8,900,594 · App. 12/310,658 · Granted Dec 2, 2014

Oral recombinant

Inventors: Quanming Zou (Chongqing, CN); Wende Tong (Chongqing, KR); Xuhu Mao (Chongqing, KR); Gang Guo (Chongqing, KR); Dongshui Lu (Chongqing, KR); Chao Wu (Chongqing, KR); Hao Zeng (Chongqing, KR); Yichao Wang (Chongqing, KR); Jun Yang (Chongqing, KR); Weijun Zhang (Chongqing, KR); Kaiyun Liu (Chongqing, KR); Ping Luo (Chongqing, KR)
Assignee: Wuhu Kangwei Biotechnology Co., Ltd
C12N9/80A61K47/26A61K39/00C07K2319/55A61K39/105C07K14/205A61K9/19C07K2319/00C07K14/245A61K2039/55544A61K2039/542
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,900,594
App. No.
12/310,658
Granted
Dec 2, 2014
Kind
B2
Abstract

The invention relates to a recombinant protein used for immunoprophylaxis of human Helicobacter pylori infection and a degradable slow-releasing microsphere-encapsulated oral vaccine preparation prepared from the same, and the preparation method thereof. Said recombinant protein is composed of A2 subunit and B subunit of the LT of enterotoxigenic Escherichia coli and urease B subunit. The vaccine provided in the invention used in human Helicobacter pylori infection is safe and effective and convenient for oral intake.

Claims (16)

1. A recombinant protein, wherein said recombinant protein is formed by fusion of an A2 subunit and a B subunit of heat-labile enterotoxin of enterotoxigenic Escherichia coli and a urease B subunit of Helicobacter pylori , wherein the amino acid sequence of the recombinant protein is presented in SEQ ID NO:2.

2. A slow-release microsphere-encapsulated oral preparation, wherein said preparation encapsulates the recombinant protein of claim 1 .

3. The microsphere-encapsulated oral preparation of claim 2 , wherein said encapsulation substances include sodium alginate, vegetable oil, calcium chloride, and chitosan.

4. The microsphere-encapsulated oral preparation of claim 2 or 3 , wherein the particle diameter of said microsphere-encapsulated preparation is 3.33 μm.

5. The microsphere-encapsulated oral preparation of claim 2 or 3 , wherein said encapsulated preparation is a freeze-dried preparation.

6. The freeze-dried preparation of claim 5 , wherein the excipient of the freeze-dried preparation is 8% mannitol, stabilizing agent is 0.05% EDTA-Na 2 , and the optimal pH value is 10.0.

7. A nucleotide sequence encoding the recombinant protein of claim 1 , wherein said nucleotide sequence is ltA2B-ureB formed by fusion of the coding gene of an A2 subunit and the coding gene of a B subunit of heat-labile enterotoxin of enterotoxigenic Escherichia coli , and the coding gene of a urease B subunit of Helicobacter pylori , wherein the nucleotide sequence is presented in SEQ ID NO: 1.

8. A recombinant plasmid, wherein said plasmid is formed by ligation of the nucleotide sequence of claim 7 and the plasmid pET-11c.

9. A method for preparing a recombinant protein wherein said recombinant protein is formed by fusion of an A2 subunit and a B subunit of heat-labile enterotoxin of enterotoxigenic Escherichia coli and urease B subunit of Helicobacter pylori , wherein said method comprises the following steps:

1) respectively cloning the coding nucleotide sequences of urease B subunit UreB or Helicobacter pylori and subunit of heat-labile enterotoxin LTA2B of enterotoxigenic Escherichia coli , wherein the amino acid sequence of the recombinant protein is presented in SEQ ID NO: 2;

2) ligating the nucleotide sequences obtained by cloning in the step 1) by the method of overlapping PCR to form fusion gene ltA2B-ureB;

3) constructing the fusion gene ltA2B-ureB on a vector, transforming a host, and expressing recombinant protein LTA2B-UreB;

4) separating and purifying the recombinant protein obtained from step 3).

10. A method for preparing an oral recombinant Helicobacter pylori vaccine, which comprises the follow steps:

(1) proportioning the recombinant protein obtained in claim 9 with sodium alginate, vegetable oil, calcium chloride, and chitosan, and preparing into a degradable slow-releasing microsphere-encapsulated preparation; and

(2) optionally preparing the slow-releasing microsphere-encapsulated preparation into a freeze-dried product.

Assignments (3)
CHANGE OF NAME Recorded Oct 23, 2014
From: CHONGQING KANG WEI BIOTECHNOLOGY CO., LTD.
To: WUHU KANGWEI BIOTECHNOLOGY CO., LTD
Reel/Frame 034423/0945 →
CHANGE OF NAME Recorded Sep 29, 2014
From: ZOU, QUANMING; TONG, WENDE, MS.; MAO, XUHU; GUO, GANG; LU, DONGSHUI; WU, CHAO; ZENG, HAO; WANG, YICHAO; YANG, JUN, MS.; ZHANG, WEIJUN; LIU, KAIYUN; LUO, PING
To: WUHU KANGWEI BIOTECHNOLOGY CO., LTD
Reel/Frame 033837/0893 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2009
From: ZOU, QUANMING; TONG, WENDE; MAO, XUHU; GUO, GANG; LU, DONGSHUI; WU, CHAO; ZENG, HAO; WANG, YICHAO; YANG, JUN; ZHANG, WEIJUN; LIU, KAIYUN; LUO, PING
To: CHONGQING KANG WEI BIOTECHNOLOGY CO., LTD.
Reel/Frame 023291/0457 →
Priority Claims (1)
CN 2006 1 0095094 · Sep 5, 2006 · national
Continuity (1)
Related Publication 20110171315A1 · Jul 14, 2011